JUUL Enters Into Consent Judgment with North Carolina


On June 28, 2021, North Carolina Attorney General Joshua Stein announced entry of a final consent judgment between JUUL Labs, Inc. (JUUL) and North Carolina. This consent judgment ends a nearly two-year legal battle and marks the first time a state successfully settled a lawsuit against JUUL, the leading U.S. e-cigarette company. North Carolina’s original complaint alleged that JUUL engaged in unfair and deceptive practices that targeted young people to use its pod-based electronic nicotine delivery system (ENDS), including downplaying the effects of nicotine, in violation of the state’s Unfair and Deceptive Trade Practices Act.[1] While JUUL denies any wrongdoing or liability in the agreement, the consent judgment prescribes several requirements and restrictions on JUUL’s continued operations in the state.

The North Carolina Consent Judgment

JUUL must pay a fine of $40 million over the next six years as part of the consent judgment. The fine is intended to be used to support various state ENDS cessation research and prevention programs. JUUL can apply for a waiver of the final $4.5 million should the North Carolina Attorney General and North Carolina Department of Health and Human Services find JUUL compliant with the agreement and that the payments, or other actions, have contributed to a “significant decline in usage of JUUL Products by Underage Individuals.”

Additionally, the consent judgment enumerates numerous conduct requirements and restrictions on JUUL’s activities within the state. Although advertised as “drastic” business changes for JUUL, many of these restrictions and requirements appear to have already been implemented by the company as part of its ongoing efforts to reinvent itself, address public health concerns, and comply with FDA requirements. The following sections of the consent judgment are organized by general activity and briefly summarize the conditions that bind JUUL.

Promotion and Marketing:

Sponsorships and Youth Education:

Retail and Internet Sales:

Health Claims:

Lastly, the consent judgment includes a “most-favored nation” clause which stipulates that if JUUL enters into a more favorable settlement or consent judgment with another state before March 31, 2025, then North Carolina may elect to seek a review of the terms of its consent judgment.

Additional Legal Issues

On the heels of the North Carolina consent judgment, Congressman Raja Krishnamoorthi (D-IL) and Senator Richard Durbin (R-TN) sent a letter to Dr. Janet Woodcock, current FDA Acting Commissioner, calling for FDA to review all documents associated with the North Carolina case against JUUL prior to FDA making a marketing authorization determination of the company’s Premarket Tobacco Product Applications (PMTAs). The letter specifically cited to Dr. Woodcock’s promise during the recent House Oversight Committee hearing on Youth Vaping to “consider a company’s prior youth targeting, bad acts, and violations of law” specifically when assessing a JUUL’s PMTAs. It will be telling to see how this all plays out in the ultimate marketing determination of the JUUL products and potential FDA post-marketing requirements.

In addition to the North Carolina consent judgment, JUUL also faces a panoply of other legal issues. JUUL is currently engrossed in similar legal battles across thirteen states, including California, New York, and Illinois. The core allegation in these suits is that JUUL’s marketing practices contributed to a public health crisis, particularly among the states’ teenage population. JUUL is also party to multidistrict litigation in the U.S. District Court for the Northern District of California.[2] The multidistrict litigation consists of individual personal injury cases, school district public nuisance cases, county and municipality cases, and class action cases.

In addition, last year the Federal Trade Commission filed an administrative complaint alleging that Altria’s acquisition of a 35% stake in JUUL—a deal totaling $12.8 billion—was a violation of federal antitrust laws.


[1] Complaint at 1, North Carolina, ex rel. Joshua H. Stain v. JUUL Labs, Inc., No. 19CVS2885 (N.C. Super. Ct. May 15, 2019), 2019 WL 7403771.

[2] Due to the level of interest in this case, the U.S. District Court for the Northern District of California created a public webpage specifically for this litigation. See In re: JUUL Labs, Inc. Marketing, Sales Practices & Products Liability Litigation, U.S. Dist. Ct. for the N. Dist. of Cal.

Ian J. Murray also contributed to this article.


© 2025 Keller and Heckman LLP
National Law Review, Volume XI, Number 193